Immunotherapy is a treatment that activates the immune system and enables it to fight cancer cells. Immunotherapy drugs are given through a vein, namely intravenously infusion. Sipuleucel-T, an immunotherapy approved by FDA for stage IV prostate cancer, is available at the Swedish Cancer Institute.
Targeted therapy is a class of drugs that are specifically active on prostate cancer cells with certain genetic mutations. For example, olaparib is an oral drug designed to treat prostate cancers with mutations in genes involved in repairing damages of DNA. There are several clinical trials of targeted therapy available at Swedish Cancer Institute.
Radiopharmaceuticals deliver radiation directly and specifically to cancer cells. For example, radium-223 dichloride (Xofigo®) specifically targets prostate cancer cells in bone.
A new class of radiopharmaceuticals, called theranostics (a combination of therapeutics and diagnostics), combine a radioactive tracer to localize cancer and another radioactive drug to deliver radiation to the sites of cancer and kill cancer cells. While theranostic drugs are yet to be approved for prostate cancer in United States, they are expected to be granted FDA approval in the near future. Clinical trials of theranostic drugs will be available to eligible patients at Swedish Cancer Institute in the coming year.